JP2006506350A - 置換1,4−ピラジン誘導体 - Google Patents

置換1,4−ピラジン誘導体 Download PDF

Info

Publication number
JP2006506350A
JP2006506350A JP2004536018A JP2004536018A JP2006506350A JP 2006506350 A JP2006506350 A JP 2006506350A JP 2004536018 A JP2004536018 A JP 2004536018A JP 2004536018 A JP2004536018 A JP 2004536018A JP 2006506350 A JP2006506350 A JP 2006506350A
Authority
JP
Japan
Prior art keywords
alkyl
substituted
ring
diethyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2004536018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506350A5 (cg-RX-API-DMAC10.html
Inventor
ジェフリー・ダブルユー・コーベット
チャン−ミン・フー
マイクル・ディー・エニス
クリスティーン・イー・フランク
ロバート・エル・ホフマン
パトリック・アール・ヴァーヘースト
Original Assignee
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファルマシア・アンド・アップジョン・カンパニー・エルエルシー filed Critical ファルマシア・アンド・アップジョン・カンパニー・エルエルシー
Publication of JP2006506350A publication Critical patent/JP2006506350A/ja
Publication of JP2006506350A5 publication Critical patent/JP2006506350A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2004536018A 2002-09-12 2003-08-27 置換1,4−ピラジン誘導体 Abandoned JP2006506350A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41026102P 2002-09-12 2002-09-12
PCT/US2003/024805 WO2004024719A1 (en) 2002-09-12 2003-08-27 Substituted 1,4-pyrazine derivatives

Publications (2)

Publication Number Publication Date
JP2006506350A true JP2006506350A (ja) 2006-02-23
JP2006506350A5 JP2006506350A5 (cg-RX-API-DMAC10.html) 2006-09-21

Family

ID=31994096

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004536018A Abandoned JP2006506350A (ja) 2002-09-12 2003-08-27 置換1,4−ピラジン誘導体

Country Status (10)

Country Link
US (1) US20040116444A1 (cg-RX-API-DMAC10.html)
EP (1) EP1539736A1 (cg-RX-API-DMAC10.html)
JP (1) JP2006506350A (cg-RX-API-DMAC10.html)
AR (1) AR041125A1 (cg-RX-API-DMAC10.html)
AU (1) AU2003269949A1 (cg-RX-API-DMAC10.html)
BR (1) BR0314139A (cg-RX-API-DMAC10.html)
CA (1) CA2494975A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA05002418A (cg-RX-API-DMAC10.html)
TW (1) TW200503717A (cg-RX-API-DMAC10.html)
WO (1) WO2004024719A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012082A (es) * 2003-05-09 2006-02-22 Pharmacia & Upjohn Co Llc Compuestos como antagonistas del receptor crf1.
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
IL311645B2 (en) * 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
PL3788049T3 (pl) 2018-05-01 2023-06-19 Revolution Medicines, Inc. Połączone z C40, C28 i C32 analogi rapamycyny jako inhibitory mTOR
EP3788050B1 (en) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
EP4531859A4 (en) 2022-05-25 2026-05-27 Revolution Medicines Inc CANCER TREATMENT METHODS USING AN MTOR INHIBITOR

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4270297A (en) * 1996-09-16 1998-04-02 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
PA8467401A1 (es) * 1998-02-17 2000-09-29 Pfizer Prod Inc Procedimiento para tratar la insuficiencia cardiaca
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
ATE307121T1 (de) * 2000-02-16 2005-11-15 Neurogen Corp Substituierte arylpyrazine

Also Published As

Publication number Publication date
US20040116444A1 (en) 2004-06-17
AR041125A1 (es) 2005-05-04
TW200503717A (en) 2005-02-01
MXPA05002418A (es) 2005-05-27
BR0314139A (pt) 2005-07-12
CA2494975A1 (en) 2004-03-25
AU2003269949A1 (en) 2004-04-30
WO2004024719A1 (en) 2004-03-25
EP1539736A1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
EP0927171B1 (en) Pyrazinones and triazinones and their derivatives thereof
JP5560278B2 (ja) キナーゼ阻害剤として有用なイミダゾピリダジンカルボニトリル
JP2004500383A (ja) 置換アリールピラジン
SK6142000A3 (en) HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINICì (54) ACETYLCHOLINE RECEPTORS
CN116867784A (zh) 吡啶衍生物及其在医药上的应用
JP2004505942A (ja) Gabaa受容体の配位子としての複素環式化合物
JP5651110B2 (ja) 新規化合物
JPS6056982A (ja) 3,6−ジ置換トリアゾロ〔3,4−a〕フタラジン誘導体、その製法および製薬学的組成物
JP2002510695A (ja) 副腎皮質刺激ホルモン放出因子(CRF)拮抗剤としてのチアゾロ[4,5−d]ピリミジンおよびピリジン
US20040116444A1 (en) Substituted 1,4-pyrazine derivatives
JP2006525993A (ja) Crf1受容体拮抗剤である化合物
JP2008503444A (ja) Crf受容体アンタゴニスト、その調製法、その医薬組成物およびその使用
CA2601600C (en) Substituted aryl 1,4-pyrazine derivatives
JP2006509729A (ja) Crf受容体モジュレータとしての5−置換−2−アリールピラジン類
JP2006525309A (ja) ピロロ(1,2−b)ピリダジン化合物、ならびにCRF−1受容体拮抗薬としてのその使用
WO2001068614A2 (en) 5-substituted arylpyrimidines
RU2330020C2 (ru) НОВЫЕ ПРОИЗВОДНЫЕ АМИНОПИРИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGIuR5
JP2005533014A (ja) 置換ピラジン誘導体
JP2006514628A (ja) Crf変調剤としてのピラジン化合物
JP2009501176A (ja) グリコーゲンシンターゼキナーゼ3阻害薬としてのピリダジン化合物
JP2021512861A (ja) 抗癌性化合物
CN120172982A (zh) 苯并二氢呋喃类三并环化合物、其药物组合物及应用
AU2007200154B2 (en) Compounds and methods for promoting smoking cessation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060804

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20090313